Further analysis of transcriptomic, proteomic, and phosphoproteomic data from the CPTAC colon cancer cohorts showed significant upregulation of tumor migration markers (TGFBR2-S553 and EPHB3) and PI3K/AKT activation (PIP4K2C and PIK3R1) in KRAS-mutated tumors, while cellular metabolism markers (DGAT1 and HINT3) and immune regulation markers (TAP1/2, IFITM1, and IFIH1-S301) were enriched in the WT KRAS tumors [23]. The gene discussed is KRAS; the disease is malignant colon neoplasm.